Bile acid sequestrants in non-healing Barrett's esophagus after endoscopic therapy - a retrospective evaluation

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00023947

Enrollment

Registered

2021-01-13

Start date

2020-11-13

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C15

Interventions

Group 1: Retrospective survey of patients with wound healing disorders. Some of these patients were treated with bile acid sequestrants at the discretion of the treating physician. The influence of th

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Patients who presented to our center between April 2014 and March 2020 and met the following criteria: - Coded principal diagnosis "adenocarcinoma of the gatroesophageal junction" (AEG), coded under ICD codes C15.9 and C16.9 - Histological confirmation of the findings - Documented endoscopically insufficient squamous reepithelialization. - Presence of endoscopic control examination in the center

Exclusion criteria

Exclusion criteria: - Squamous cell carcinoma - Wound healing disorder after oesophageal resection

Design outcomes

Primary

Measure	Time frame
- Improvement of endoscopic healing under applied therapy regimens. - Achieving complete squamous cell healing.	—

Secondary

Measure	Time frame
- Influence of patient characteristics. - Influence of extent of initial Barrett's esophagus and maximal dys- or neoplasia. - Influence of endoscopic therapy. - Influence of relevant concomitant medication. - Occurrence of dys- or neoplasia in "Neobarrett's".	—

Countries

Germany

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026